Nouscom will present new phase 1b/2 data on its off‑the‑shelf cancer immunotherapy NOUS‑209 at the European Society for Medical Oncology Congress 2026, taking place from 23–27 October in Madrid.
The oral presentation will focus on re‑treatment and long‑term follow‑up in Lynch Syndrome carriers, a population with up to 80% lifetime risk of developing cancer.
The talk, delivered by Eduardo Vilar‑Sanchez, M.D., Ph.D., from The University of Texas MD Anderson Cancer Center, will outline safety and immunogenicity findings from NOUS‑209 re‑vaccination together with clinical follow‑up extending beyond one year.
The data aim to strengthen evidence supporting NOUS‑209 as a potential cancer interception immunotherapy for Lynch Syndrome carriers.
Marina Udier, Chief Executive Officer of Nouscom, said: “This is yet another recognition of the outstanding data we have generated for NOUS‑209 in Lynch Syndrome – the fourth oral presentation of data from this trial, following AACR 2025 and SITC 2023 and 2025.”
She added: “Together with our recent FDA Fast Track Designation, it strengthens our conviction and momentum as we advance NOUS‑209 into a registration‑enabling trial to deliver the first cancer interception immunotherapy for Lynch Syndrome carriers who face up to 80% lifetime risk of developing cancer.”
The NOUS‑209 programme is supported by phase 1b/2 data published in Nature Medicine, showing that the therapy was safe and induced broad, potent, functional and durable T cell responses.
Annual re‑treatment boosted these responses, and no new advanced adenomas were detected one year after treatment, providing early clinical evidence of cancer interception in Lynch Syndrome carriers.
The clinical trial, NCT05078866, was conducted through a collaboration between the National Cancer Institute’s Cancer Prevention Clinical Trials Network and the iCAN‑PREVENT consortium at MD Anderson, with primary funding from the NCI and additional support from the Data Management, Auditing and Coordination Center.
